IRVINE, Calif. – November 18, 2025 – BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring the company's commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.
The peptide BU, which is already fully operational, will be led by Fengping Xiao, Ph.D. Dr. Xiao brings decades of experience to his newly created role spanning from drug discovery through development, with a focus on both small molecules and peptides.
Over the past couple of years, BioDuro has built comprehensive peptide capabilities across multiple technology platforms including its newly established DNA-encoded library (DEL) screening service, and AI-enabled design for peptides. The new BU will see the integration of BioDuro's chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product capabilities into one specialized platform, and the newly created BU will bring together the company's significant cross-functional peptide expertise, dedicated resources and customized workflows to accelerate peptide drug discovery and development under one roof.
"Our goal is to provide comprehensive scientific expertise and fully integrated solutions by bringing together the best minds and technologies to deliver optimal results for our global partners," said Dr. Xiao.
"The creation of this Peptide BU marks a pivotal milestone for BioDuro," added Armin Spura, Ph.D., Chief Executive Officer of BioDuro. "Our mission is to build the most advanced peptide platform, powered by exceptional science, state-of-the-art technology, and a world-class team, to meet the growing customer demand for complex peptide therapeutics worldwide."
About BioDuro
BioDuro, an Advent International portfolio company, is a CRDMO with a 29-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, and over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product.
Media Enquiries
Christina Coby
Associate Director, BioDuro
Email: christina.coby@bioduro.com
Mobile: +1 (619) 414 7409
Chris Halling
Director, Communications & Content, Orientation Marketing
Email: Chris.Halling@orientation.agency
Mobile: +44 (0)7580 041073
Home
